Halozyme Therapeutics (HALO) Tops Q3 EPS by 11c, provides guidance

Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $1.72, $0.11 better than the analyst estimate of $1.61. Revenue for the quarter came in at $354 million versus the consensus estimate of $340.12 million.

GUIDANCE:

Halozyme Therapeutics sees FY2025 EPS of $6.10-$6.50, versus the consensus of $5.18. Halozyme Therapeutics sees FY2025 revenue of $1.3-1.375 billion, versus the consensus of $1 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)